AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29624254 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release nimesulide formulation
Number of subjects: 12
Study 29624254 — intervention group
Group type: COMPARATOR
Intervention: Reference nimesulide formulation
Number of subjects: 12
Study 29624254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioequivalence results
Number of subjects: 12
Study 26245847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral sitting training on a platform tilted 10° to the paretic side, 60 times/session, 6 sessions/week
Number of subjects: 30
Study 26245847 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with no additional training
Number of subjects: 30
Study 24673496 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg luseogliflozin
Number of subjects: 282
Study 24673496 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg luseogliflozin
Number of subjects: 282
Study 24673496 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg luseogliflozin
Number of subjects: 282
Study 24673496 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg luseogliflozin
Number of subjects: 282
Study 24673496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 21566204 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (6.4 µmol/min)
Number of subjects: 10
Study 21566204 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA in PGF(2α)‐preconstricted veins
Number of subjects: 10
Study 19142567 — intervention group
Group type: COMPARATOR
Intervention: EPA&DHA (daily DHA/EPA capsules)
Number of subjects: 324
Study 19142567 — intervention group
Group type: COMPARATOR
Intervention: Fatty fish (150 g salmon, three times per week)
Number of subjects: 324
Study 19142567 — intervention group
Group type: COMPARATOR
Intervention: Lean fish (150 g cod, three times per week)
Number of subjects: 324
Study 19142567 — intervention group
Group type: COMPARATOR
Intervention: Control (no seafood)
Number of subjects: 324
Study 17470016 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal pathogens levels in preterm deliveries
Number of subjects: 31
Study 17470016 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal anti-Porphyromonas gingivalis IgG levels
Number of subjects: 31
Study 17470016 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels of P. gingivalis, Tannerella forsythia, Prevotella intermedia, and Prevotella nigrescens postpartum
Number of subjects: 31
Study 17470016 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint effects of red and orange microbial clusters
Number of subjects: 31
Study 16873699 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (increasing physical activity, improving diet, decreasing body weight)
Number of subjects: 522
Study 16873699 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 522
Study 16873699 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study 12623959 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine (10 mg/d, n=14)
Number of subjects: 28
Study 12623959 — intervention group
Group type: EXPERIMENTAL
Intervention: lercanidipine (10 mg/d, n=14)
Number of subjects: 28
Study 12623959 — intervention group
Group type: COMPARATOR
Intervention: acute drug administration
Number of subjects: 28
Study 10519687 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice
Number of subjects: 0
Study 10519687 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of health education literature
Number of subjects: 0
Study 10519687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of brief advice and health education literature
Number of subjects: 0
Study 10519687 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8901795 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.5 mg pure acetylsalicylic acid
Number of subjects: 17
Study 8901795 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.1 mg salicylic acid
Number of subjects: 17
Study 8901795 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected diets
Number of subjects: 17
Study 1912752 — intervention group
Group type: EXPERIMENTAL
Intervention: Negotiable withdrawal schedule
Number of subjects: 0
Study 1912752 — intervention group
Group type: COMPARATOR
Intervention: Fixed (non-negotiable) dose reduction schedule
Number of subjects: 0
Study 1912752 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 7120089 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg perphenazine tablet
Number of subjects: 7
Study 7120089 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 8 mg perphenazine tablets
Number of subjects: 7
Study 7120089 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg amitriptyline tablet
Number of subjects: 7
Study 7120089 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg amitriptyline tablet with 10 mg amitriptyline and 4 mg perphenazine combination tablet
Number of subjects: 7
Study 7120089 — intervention group
Group type: EXPERIMENTAL
Intervention: Two combination tablets (10 mg amitriptyline and 4 mg perphenazine each)
Number of subjects: 7
Study 7120089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30520702 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing (VC) assessment
Number of subjects: 19
Study 30520702 — intervention group
Group type: COMPARATOR
Intervention: In-person (IP) assessment
Number of subjects: 19
Study 28719594 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 64
Study 28719594 — intervention group
Group type: COMPARATOR
Intervention: Cyproheptadine
Number of subjects: 64
Study 28695660 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthacarin (2×1 capsule/day for 4 weeks)
Number of subjects: 114
Study 28695660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2×1 capsule/day for 4 weeks)
Number of subjects: 114
Study 25544635 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in both anterior and posterior regions
Number of subjects: 190
Study 25544635 — intervention group
Group type: COMPARATOR
Intervention: Treatment in posterior region only
Number of subjects: 190
Study 23588557 — intervention group
Group type: EXPERIMENTAL
Intervention: GBA1 mutation carriers
Number of subjects: 721
Study 21041245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 18154
Study 21041245 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 18154
Study 18492259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ditrame-Plus (early HIV diagnosis and cotrimoxazole prophylaxis)
Number of subjects: 98
Study 18492259 — intervention group
Group type: COMPARATOR
Intervention: Ditrame (standard care without cotrimoxazole prophylaxis)
Number of subjects: 98
Study 18492259 — intervention group
Group type: COMPARATOR
Intervention: Ditrame-Plus vs Ditrame
Number of subjects: 98
Study 18492259 — intervention group
Group type: COMPARATOR
Intervention: Maternal death
Number of subjects: 98
Study 16178052 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave-assisted silylation (MAS) followed by gas chromatography/mass spectrometry (GC/MS)
Number of subjects: 0
Study 12695241 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost once a day
Number of subjects: 20
Study 12695241 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine twice a day
Number of subjects: 20
Study 12695241 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of timolol and dorzolamide twice a day
Number of subjects: 20
Study 10809861 — intervention group
Group type: EXPERIMENTAL
Intervention: Open wounds
Number of subjects: 0
Study 10809861 — intervention group
Group type: COMPARATOR
Intervention: Intact blisters
Number of subjects: 0
Study 10809861 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol-pretreated open wounds
Number of subjects: 0
Study 8690826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate (50-150 mg/day)
Number of subjects: 150
Study 8690826 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (80-240 mg/day)
Number of subjects: 150
Study 8690826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 2070243 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression anti-embolism stocking
Number of subjects: 40
Study 2070243 — intervention group
Group type: COMPARATOR
Intervention: Control (no stocking)
Number of subjects: 40
Study 6137978 — intervention group
Group type: COMPARATOR
Intervention: suxamethonium 1 mg X kg‐1 in a single bolus followed by an infusion (group A)
Number of subjects: 40
Study 6137978 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium 0.05 mg X kg‐1 (group B)
Number of subjects: 40
Study 6137978 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium 0.06 mg X kg‐1 (group C)
Number of subjects: 40
Study 6137978 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium 0.07 mg X kg‐1 (group D)
Number of subjects: 40
Study 29973130 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted remote consultation (RMC)
Number of subjects: 389
Study 29973130 — intervention group
Group type: COMPARATOR
Intervention: Standard consultation (UNN)
Number of subjects: 389
Study 27686473 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Autobiographical Memories (AMs) shared first as general (AK) then specific (EAM)
Number of subjects: 148
Study 27686473 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Autobiographical Memories (AMs) shared first as general (AK) then specific (EAM)
Number of subjects: 148
Study 27686473 — intervention group
Group type: COMPARATOR
Intervention: Order of sharing (AK first or EAM first)
Number of subjects: 148
Study 26284720 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (3.0 mg)
Number of subjects: 846
Study 26284720 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg)
Number of subjects: 846
Study 26284720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846
Study 24858158 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal lidocaine gel (Group I)
Number of subjects: 60
Study 24858158 — intervention group
Group type: COMPARATOR
Intervention: Intraprostatic lidocaine injection with intra rectal gel (Group II)
Number of subjects: 60
Study 22037225 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq™ laryngoscope
Number of subjects: 30
Study 22037225 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope™
Number of subjects: 30
Study 22037225 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Fastrach™
Number of subjects: 30
Study 19848198 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong Injection (DHI)
Number of subjects: 100
Study 19848198 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment only)
Number of subjects: 100
Study 17854429 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR9 gene polymorphisms
Number of subjects: 200
Study 17854429 — intervention group
Group type: COMPARATOR
Intervention: Control group (102 randomized controls)
Number of subjects: 200
Study 15590856 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone injection with nimesulide (200 mg for seven days)
Number of subjects: 160
Study 15590856 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone injection with placebo (for seven days)
Number of subjects: 160
Study 15590856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide group
Number of subjects: 160
Study 15590856 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 160
Study 11593959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (group or individual)
Number of subjects: 36
Study 11593959 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment
Number of subjects: 36
Study 11593959 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral treatment
Number of subjects: 36
Study 9141548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) therapy (0.625 mg daily)
Number of subjects: 875
Study 9141548 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE in combination with medroxyprogesterone acetate (2.5 mg daily)
Number of subjects: 875
Study 9141548 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE in combination with medroxyprogesterone acetate (10 mg daily on days 1-12)
Number of subjects: 875
Study 9141548 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE in combination with micronized progesterone (200 mg daily on days 1-12)
Number of subjects: 875
Study 9141548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study 9141548 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE therapy
Number of subjects: 875
Study 7956109 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management in conjunction with psychosocial rehabilitation
Number of subjects: 0
Study 7956109 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial rehabilitation only
Number of subjects: 0
Study 3113291 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg morphine
Number of subjects: 122
Study 3113291 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg butorphanol
Number of subjects: 122
Study 3113291 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg butorphanol
Number of subjects: 122
Study 3113291 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg butorphanol
Number of subjects: 122
Study 29553843 — intervention group
Group type: EXPERIMENTAL
Intervention: Quince sauce (QS) 10 mg after meals
Number of subjects: 137
Study 29553843 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 137
Study 27370396 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard radiotherapy (RT)
Number of subjects: 0
Study 24874200 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous HF hospitalization
Number of subjects: 7599
Study 24874200 — intervention group
Group type: EXPERIMENTAL
Intervention: Time interval from previous HF hospitalization to randomization
Number of subjects: 7599
Study 24874200 — intervention group
Group type: EXPERIMENTAL
Intervention: HF with preserved ejection fraction and previous HF hospitalization in the 6 months before randomization
Number of subjects: 7599
Study 23486511 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (20 g)
Number of subjects: 161
Study 23486511 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric carbohydrate
Number of subjects: 161
Study 20678148 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 20
Study 20678148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18988300 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Slow EEG phenotype
Number of subjects: 0
Study 18988300 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowed Alpha Peak Frequency EEG phenotype
Number of subjects: 0
Study 18988300 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0
Study 16635635 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made ankle-foot orthosis (AFO)
Number of subjects: 13
Study 16635635 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid hindfoot orthosis (HFO-R)
Number of subjects: 13
Study 16635635 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulated hindfoot orthosis (HFO-A)
Number of subjects: 13
Study 12796726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical surgical randomized controlled trials (RCTs)
Number of subjects: 0
Study 11077380 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass combined with calcium sulfate as a graft material
Number of subjects: 16
Study 11077380 — intervention group
Group type: COMPARATOR
Intervention: Control (no graft or calcium sulfate)
Number of subjects: 16
Study 9587554 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase and heparin
Number of subjects: 10
Study 9587554 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 10
Study 7943865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO)
Number of subjects: 49
Study 7943865 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bolus injection of subnarcotic doses of sodium hydroxybutyrate and sodium thiopental
Number of subjects: 49
Study 3091055 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 10 mg three times daily
Number of subjects: 20
Study 3091055 — intervention group
Group type: COMPARATOR
Intervention: Transdermal nitrate (TN) one 10 cm2 patch daily
Number of subjects: 20
Study 3091055 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitrate (TN)
Number of subjects: 20
Study 3091055 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 20
Study 30039328 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Families intervention
Number of subjects: 245
Study 30773357 — intervention group
Group type: EXPERIMENTAL
Intervention: Collum Femoris Preserving (CFP) group
Number of subjects: 140
Study 30773357 — intervention group
Group type: COMPARATOR
Intervention: Zweymüller group
Number of subjects: 140
Study 28204189 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 1341
Study 28204189 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 1341
Study 28204189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 1341
Study 28204189 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 1341
Study 28204189 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 1341
Study 28204189 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1341
Study 28204189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1341
Study 28204189 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 1341
Study 28204189 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib
Number of subjects: 1341
Study 28204189 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 1341
Study 25555450 — intervention group
Group type: EXPERIMENTAL
Intervention: Single i.v. dose of MAPC (10 million cells/kg)
Number of subjects: 36
Study 25555450 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly for up to 5 doses of MAPC (1 or 5 million cells/kg)
Number of subjects: 36
Study 25555450 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPC infusions
Number of subjects: 36
Study 23766098 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid OLE (76.6 mg oleuropein, 14.5 mg hydroxytyrosol)
Number of subjects: 9
Study 23766098 — intervention group
Group type: COMPARATOR
Intervention: Capsulated OLE (76.6 mg oleuropein, 14.5 mg hydroxytyrosol)
Number of subjects: 9
Study 23766098 — intervention group
Group type: EXPERIMENTAL
Intervention: Males receiving OLE
Number of subjects: 9
Study 23766098 — intervention group
Group type: EXPERIMENTAL
Intervention: OLE (both formulations)
Number of subjects: 9
Study 21272325 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervisor telephone contact (STC) during maternity leave
Number of subjects: 541
Study 21272325 — intervention group
Group type: COMPARATOR
Intervention: Common practice (CP)
Number of subjects: 541
Study 19561152 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg o.d.
Number of subjects: 16
Study 19561152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16757720 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT + SRS
Number of subjects: 132
Study 16757720 — intervention group
Group type: COMPARATOR
Intervention: SRS alone
Number of subjects: 132
Study 15087635 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil with 6 ml/h background infusion
Number of subjects: 133
Study 15087635 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil with 9 ml/h background infusion
Number of subjects: 133
Study 15087635 — intervention group
Group type: COMPARATOR
Intervention: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil without background infusion
Number of subjects: 133
Study 15087635 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil (all groups)
Number of subjects: 133
Study 11834229 — intervention group
Group type: EXPERIMENTAL
Intervention: One tablet of 750 microg levonorgestrel at time -12 h and one tablet at time 0 (Group A)
Number of subjects: 24
Study 11834229 — intervention group
Group type: EXPERIMENTAL
Intervention: One tablet of 750 microg levonorgestrel at time 0 (Group B)
Number of subjects: 24
Study 11834229 — intervention group
Group type: EXPERIMENTAL
Intervention: One tablet of 750 microg levonorgestrel at time -24 h and one tablet at time 0 (Group C)
Number of subjects: 24
Study 9926761 — intervention group
Group type: EXPERIMENTAL
Intervention: DBM+CS implant
Number of subjects: 26
Study 9926761 — intervention group
Group type: COMPARATOR
Intervention: Gingival flap surgery (GFS)
Number of subjects: 26
Study 8050452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with 6 g of highly concentrated ethyl esters of EPA and DHA daily for 4 months.
Number of subjects: 41
Study 8050452 — intervention group
Group type: COMPARATOR
Intervention: Dietary supplementation with 6 g of corn oil daily for 4 months (Control).
Number of subjects: 41
Study 3390111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of thiethylperazine (10 mg) and cimetidine (300 mg)
Number of subjects: 0
Study 3390111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of thiethylperazine (10 mg), cimetidine (300 mg), and promethazine (25 mg)
Number of subjects: 0
Study 3390111 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 0
Study 8245236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% shampoo
Number of subjects: 246
Study 8245236 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium sulfide 2.5% shampoo
Number of subjects: 246
Study 8245236 — intervention group
Group type: COMPARATOR
Intervention: Placebo shampoo
Number of subjects: 246
Study 330575 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily intramuscular injection of sisomicin (160 mg)
Number of subjects: 50
Study 330575 — intervention group
Group type: COMPARATOR
Intervention: Two daily injections of sisomicin (80 mg)
Number of subjects: 50